Industry Source Confirms Hong Kong Main Port Of Mainland China Counterfeit Drugs
This article was originally published in PharmAsia News
Hong Kong remains at the center of the flow of counterfeit drugs from mainland China to other countries, according to a pharmacy industry source in the city. The source said illicit activities are able to move more easily through Hong Kong than other places because it is a free port. Counterfeit drugs on foreign markets, primarily from the Chinese mainland, include those for treating cholesterol, diabetes and heart and liver problems. The Office of the U.S. Trade Representative issued a report last year naming Hong Kong, the Philippines, Thailand, Paraguay and Ukraine as having "significant problems" with smuggled counterfeits. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.